Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization

As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program - including scaling back from its industry-leading approach of investing a high percentage of sales on R&D